# TRIOAR

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trioar

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.trioar.co.kr/
- Total disclosed funding: $27M
- Latest round: Series B (Aug 28, 2025)
- Investors on record: 15

## About

Based in Daejeon, South Korea, and founded in 2021, TRIOAR is a new drug development company that develops a platform technology that improves the limitations of antibody therapeutics, antibody-drug conjugates, or ADCs, and seeks to develop next-generation drugs. In February 2022, TRIOAR raised pre-series A funding from Bokwang Venture Capital, IMM Investment, and KB Investment. As of February 2022, Mr. Seong-ho Woo is the CEO of TRIOAR. In May 2023, TRIOAR raised KRW 12 billion in series A funding led by new investor LSK Investment, with participation from other new investors Shinhan Capital, Medytox Venture Investment, Kiwoom Investment, and Enlight Ventures. Returning investors KB Investment and Bokwang Venture Capital also participated in this round. In July 2025, TRIOAR raised KRW 22.5 billion in series B funding led by new investor WOORI Venture Partners, with participation from other new investors Shinhan Venture Investment, Hyundai Venture Investment, Regent Partners, and Sneak Peek Investment. Returning investors IMM Investment, LSK Investment, KB Investment, Kiwoom Investment, Shinhan Capital, and GeneN Investment Partners also participated in the round. The product pipeline of TRIOAR includes A-01, P-01, T-01, T-02, T-03, TA-01, TA-02, I-01, E-01, and B-02 for indications, such as breast cancer, solid cancer, breast cancer, TNBC, gastric cancer, solid cancer blood cancer, PDAC, and NSCLC. In addition, the company provides a platform technology that can be applied to multiple targets in multiple functional areas. The company plans to use its proceeds from February 2022 funding in research and development for platform technology and expand its company globally. The company will use the May funding to advance its technology and expand its business to secure more complete platform technology and new drug candidates. The company will use the 2025 funding to speed up the development of its upcoming projects and concentrate on comprehensive research and development efforts.

## Funding rounds

- Series B, Aug 28, 2025, $1.8M — CKD Venture Capital
- Series B, Jul 17, 2025, $16M — Hyundai Venture Investment, Shinhan Venture Investment, KB Investment, WOORI Venture Partners, IMM Investment, Kiwoom Investment, Shinhan Capital, LSK Investment, Sneak Peek Investment, GeneN Investment Partners, Regent Partners
- Series A, May 23, 2023, $9M — KB Investment, Bokwang Venture Capital, Shinhan Capital, Kiwoom Investment, LSK Investment, Enlight Ventures, Medytox Venture Investment

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A, Series B
- Bokwang Venture Capital (https://capitalatlas.ai/funds/bokwang-venture-capital) — Series A
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series A, Series B
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A, Series B
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A, Series B
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Series A
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A
- Hyundai Venture Investment (https://capitalatlas.ai/funds/hyundai-venture-investment) — Series B
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series B
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series B
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series B
- Sneak Peek Investment (https://capitalatlas.ai/funds/sneak-peek-investment) — Series B
- GeneN Investment Partners (https://capitalatlas.ai/funds/genen-investment-partners) — Series B
- Regent Partners (https://capitalatlas.ai/funds/regent-partners) — Series B
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B